NCT00157040View on ClinicalTrials.gov

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 7, 2002

Primary Completion Date

January 4, 2005

Study Completion Date

January 4, 2005

Conditions
Hemophilia A
Interventions
DRUG

Antihemophilic factor, recombinant, manufactured protein-free

Trial Locations (12)

19104

Children´s Hospital of Philadelphia, Philadelphia

30322

Emory University, Department of Pediatrics, Atlanta

46260

Indiana Hemophilia and Thrombosis Center, Indianapolis

48109

University of Michigan Hemophilia Treatment Center, Ann Arbor

48201

Children´s Hospital of Michigan, Detroit

52242

University of Iowa Hospitals and Clinics, Iowa Regional Hemophilia Center, Department of Pediatrics, Iowa City

60614

Children´s Memorial Hospital, Chicago

61614

Comprehensive Bleeding Disorders Center, Peoria

77030

University of Texas Health Science Center, Houston

90027

Children´s Hospital Los Angeles, Los Angeles

M5G 1X8

Hospital for Sick Children, Division of Hematology/Oncology, Toronto

00927

University Pediatric Hospital, San Juan

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT00157040 - Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A | Biotech Hunter | Biotech Hunter